From wiki:
Imugene began as a research project in the laboratory of Professor Ursula Wiedermann at the Medical University of Vienna. Over the nine years from 2004 Wiedermann et al. had developed a B cell peptide cancer immunotherapy that could induce an antibody response targeting HER-2 overexpressing tumours. In 2012 a start-up company called Biolife Science had been incorporated to develop this immunotherapy. Early-stage funding was secured from Australian and US investors in 2013, after which Biolife was taken public in December 2013 in a reverse takeover of an Australian drug development company called Imugene, whose name was retained after the merger
Charting Only., page-2349
-
-
- There are more pages in this discussion • 177 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.1¢ |
Change
-0.002(3.77%) |
Mkt cap ! $376.9M |
Open | High | Low | Value | Volume |
5.2¢ | 5.2¢ | 5.0¢ | $669.7K | 13.07M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 1074997 | 5.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.2¢ | 1209633 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 1074997 | 0.051 |
43 | 3560894 | 0.050 |
33 | 3784850 | 0.049 |
19 | 1296168 | 0.048 |
11 | 961292 | 0.047 |
Price($) | Vol. | No. |
---|---|---|
0.052 | 1209633 | 6 |
0.053 | 2764169 | 16 |
0.054 | 1794757 | 7 |
0.055 | 1524326 | 12 |
0.056 | 633333 | 4 |
Last trade - 16.10pm 05/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |